Skip to content
Screener

PP&E (Net) at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$7.79B+5.7%
Amgen logo
AmgenAMGN
$8.55B+24.7%
WHW
Whitehawk TherapeuticsWHWK
$2K-92.0%
Aura Biosciences, Inc. logo
Aura Biosciences, Inc.AURA
$2.47M-20.5%
Tango Therapeutics logo
Tango TherapeuticsTNGX
$6.38M-15.4%
Eikon Therapeutics, Inc. logo
Eikon Therapeutics, Inc.EIKN
$138.07M

Other financials

Income statement

See full
Revenue$6.6M
Operating income-$108.5M-28.6%
Net income-$98.5M-36.5%
EPS (diluted)-$1.11-35.4%

Balance sheet

See full
Cash & equivalents$157.5M+21.2%
Total debt$28.6M+10.1%
Total equity$937.3M-8.5%
Total assets$1.0B-6.4%

Cash flow

See full
Operating cash flow-$75.2M-24.6%
CapEx$967.0K-27.3%
Free cash flow-$76.1M-23.5%

Valuation

See full
Market cap$3.49B+68.5%
Enterprise value$3.36B+69.4%
P/S15×+10.3×

Profitability

See full
Operating margin-4,671.1%-5,434pp
Net margin-3,921.1%-4,562pp
FCF margin-3,592%-4,290pp

Returns & leverage

See full
Return on equity-14.3%-5.0pp
Debt / equity0.0×
Current ratio10.7×-3.2×

Where this comes from

Reported directly by IDEAYA Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentNet.

The source filing: IDEAYA Biosciences, Inc.’s 10-Q, filed May 5, 2026.

Filed
May 5, 2026, 4:05 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-206357
Line itemMarch 31, 2026December 31, 2025
Total current assets696,107666,727
Restricted cash1,2811,015
Long-term marketable securities301,713410,297
Property and equipment, net8,6348,217
Right-of-use assets22,61323,068
Total assets$1,030,348$1,109,324
Liabilities and Stockholders’ Equity
Current liabilities

Item 1. Financial Statements (UNAUDITED).

FAQ

What is IDEAYA Biosciences, Inc.'s PP&E (net)?
IDEAYA Biosciences, Inc. (IDYA) reported PP&E (net) of $8.63M in Q1 2026.
How has IDEAYA Biosciences, Inc.'s PP&E (net) changed year-over-year?
IDEAYA Biosciences, Inc.'s PP&E (net) decreased by 2.7% year-over-year, from $8.87M to $8.63M.
What is the long-term trend for IDEAYA Biosciences, Inc.'s PP&E (net)?
Over 5 years (2020 to 2025), IDEAYA Biosciences, Inc.'s PP&E (net) has grown at a 14.0% compound annual growth rate (CAGR), from $4.27M to $8.22M.
What does PP&E (net) mean?
Total property, plant, and equipment minus accumulated depreciation — the net book value of all tangible long-lived assets.

Ask your AI about IDEAYA Biosciences, Inc.'s pp&e (net).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude